Physician profile
Brian Michael Koch
NPI 1184895476
$2,499.36
in general payments reported to CMS, 2019-2025
31 companies · $209 in 2025
The $209 reported for 2025 was less than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $365 · 2020: $213 · 2021: $367 · 2022: $368 · 2023: $275 · 2024: $702 · 2025: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,186.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $893.49 | 2019-2025 | Eterna, Proclaim, Absolute Pro |
| Boston Scientific Corporation | $237.40 | 2019-2025 | Wavewriter Alpha Prime 16, Superion Indirect Decompression System |
| Medtronic, INC. | $211.01 | 2021-2025 | Intellis Adaptivestim, Kyphon Express II Kyphopak Tray |
| Abbvie INC. | $206.79 | 2021-2022 | |
| Ucb, INC. | $160.51 | 2019-2022 | |
| Spinal Simplicity, LLC | $115.67 | 2023-2025 | Ha Minuteman G3-R |
| Virtus Pharmaceuticals LLC | $94.64 | 2023-2025 | Levorphanol Tartrate |
| Nevro Corp. | $75.26 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.24 | 2024-2025 | Relistor |
| Amgen INC. | $44.49 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $40.39 | 2021-2022 | |
| Lundbeck LLC | $38.29 | 2020-2025 | Vyepti |
| Mdd US Operations, LLC | $25.44 | 2019 | |
| Tersera Therapeutics LLC | $24.82 | 2019 | |
| Biotronik Nro, INC. | $24.19 | 2025 | Prospera |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $19.33 | 2024 | Xtampza |
| Nalu Medical, INC. | $18.84 | 2024 | Nalu Neurostimulation System |
| Eisai INC. | $18.42 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.26 | 2025 | Rexulti |
| Neurocrine Biosciences, INC. | $17.44 | 2019 | |
| Supernus Pharmaceuticals, INC. | $17.19 | 2021 | |
| Scilex Pharmaceuticals INC. | $16.13 | 2021 | |
| Heron Therapeutics, INC. | $15.83 | 2024 | Zynrelef |
| Biohaven Pharmaceutical Holding Company LTD. | $15.81 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.99 | 2022 | |
| Assertio Therapeutics, INC. | $14.29 | 2019 | |
| Upsher-Smith Laboratories LLC | $12.92 | 2019 | |
| Strongbridge US INC. | $12.27 | 2019 | |
| Sk Life Science, INC. | $11.99 | 2020 | |
| Medtronic USA, INC. | $11.84 | 2020 | |
| Zyla Life Sciences, INC. | $11.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Koch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.